Abstract
Our previous trial with a docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen showed high response rates in metastatic squamous cell carcinoma of the esophagus (SCCE). The observed increased toxicity of the DCF regimen, however, was clinically harmful. S-1, an oral anticancer drug, has been approved as a combination therapy for SCCE, and alternate-day regimen with S-1 has shown lower levels of toxicity. This prospective single-center phase I/II trial examines the efficacy and toxicity of a combination of docetaxel, cisplatin, and an alternate-day regimen of S-1 (modified DCS) for patients with metastatic SCCE. We use a two-stage design. Phase I is undertaken to determine the maximum tolerated dose and the recommended dose. The phase I trial adopts a three-patient cohort with escalating dose study design. In the phase II trial, the primary endpoint is the assessment of the overall response rate (Response Evaluation Criteria in Solid Tumors 1.1). The secondary endpoints are the evaluation of drug-related toxicity (National Cancer Institute Common Toxicity Criteria 4.0), overall survival, and progression-free survival. Fifty patients with metastatic SCCE participate in the phase II section. This study protocol is the first to t...Continue Reading
References
Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J A AjaniC Mountain
Jul 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H BleibergT Sahmoud
Jul 19, 2001·Anti-cancer Drugs·M B PoleeA Van der Gaast
Nov 2, 2001·Japanese Journal of Clinical Oncology·K HayashiH Fukuda
Jun 29, 2004·International Journal of Clinical Oncology·Wataru AraiTetsuhiko Shirasaka
Nov 10, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Hiroaki TakahashiMasao Hosokawa
Jan 14, 2010·British Journal of Cancer·N C TebbuttUNKNOWN Australasian Gastro-Intestinal Trials Group
Mar 3, 2010·International Journal of Clinical Oncology·Kazuya SakumaTetsuhiko Shirasaka
Jul 23, 2011·Oncology·Makoto YamasakiYuichiro Doki
Feb 5, 2013·Lancet·Arjun PennathurJames D Luketich
May 22, 2013·Oncology·Hiroaki IwaseEriko Kato
Feb 25, 2014·Cancer Chemotherapy and Pharmacology·Hyun ChangJoo-Hang Kim
Jul 22, 2014·Cancer Science·Shuichi HironakaUNKNOWN Japan Esophageal Oncology Group/Japan Clinical Oncology Group
Aug 8, 2015·Cancer Science·Makoto TaharaAtsushi Ohtsu
Jan 5, 2016·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·T OjimaH Yamaue
Jun 28, 2016·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·UNKNOWN Japanese Gastric Cancer Association
Nov 22, 2016·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·Y BabaH Baba
Mar 3, 2017·Cancer Chemotherapy and Pharmacology·Hiroki YamaueTetsuhiko Shirasaka